Why NovoCure Limited’s (NVCR) Stock Is Down 5.49%
As of Thursday, October 08, NovoCure Limited’s NVCR share price has dipped by 5.49%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Commentary & Analysis
Which Is a Better Investment, AtriCure, Inc. or NovoCure Limited Stock?
Learn more about whether AtriCure, Inc. or NovoCure Limited is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Why NovoCure Limited’s (NVCR) Stock Is Up 6.77%
As of Monday, August 10, NovoCure Limited’s NVCR share price has surged by 6.77%, which has investors questioning if this is right time to sell.Michael Rose
Is NovoCure Limited (NVCR) Overvalued?
We dive into why NovoCure Limited (NVCR) could be considered overvalued on 2026-08-06, based on AAII’s Value Score and Grade.Rosalio Madrigal
Why NovoCure Limited’s (NVCR) Stock Is Up 5.53%
As of Monday, August 03, NovoCure Limited’s NVCR share price has surged by 5.53%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | NVCR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,697.8 | $385.5 | 52% |
|
| Shares Out (Mil) | 116.0 | 40.8 | 65% |
|
| Institutional Ownership | 90.5% | 83.0% | 58% |
|
| Float (Mil) | 96.4 | 35.5 | 60% |
|
| Beta | 0.93 | 0.85 | 56% |
|
| Avg Daily Volume (000s) | 1,745 | 321 | 79% |
|
| Price Change (52-week) |
1.6% | 64.6% | 54% |
|
| Growth | NVCR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 5.8% | 11.8% | 40% |
|
| Net Income (5yr) | (54.8%) | (5.5%) | 6% |
|
| EPS (5yr) | (54.4%) | 10.2% | 3 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (23.3%) | (15.5%) | 28% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.235) | ($1.235) | ($0.806) | |
| Month Ago EPS | ($0.245) | ($1.251) | ($0.816) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 2 | 1 | |
| Three Months Ago EPS | ($0.327) | ($1.594) | ($1.193) | |
| Year/Year Chg | 74.1% | 1.1% | (62.6%) | |
| Financials | NVCR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $699 | $155 | 45% |
|
| Net Income (TTM) (Mil) | ($149) | ($9) | 9% |
|
| EPS (TTM) | ($1.308) | ($0.400) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($2) | 28% |
|
| Net Cash Flow (TTM) (Mil) | ($49) | $1 | 20% |
|
| Long-Term Debt (Q1) (Mil) | $233 | $27 | 51% |
|
| Enterprise Value (Q1) (Mil) | $1,848 | $418 | 48% |
|
| Valuation | NVCR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.03 | 2.69 | 79% |
|
| P/E | na | 24.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.5 | na |
|
| Ratios | NVCR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 76.4% | 58.5% | 86% |
|
| Net Margin | (21.2%) | (6.9%) | 16% |
|
| ROA | (14.6%) | (12.2%) | 23% |
|
| ROE | (43.2%) | (10.5%) | 17% |
|
| Liabilities to Assets | 57.5% | 47.2% | 51% |
|
| F-Score | 3 | 4 | 18% |
|
NovoCure Limited did not pass any screens on 10/9/2026.
